To evaluate the effectiveness and complications associated with inferior vena cava (IVC) filters in patients with acute pulmonary embolism (APE) and venous thromboembolism.
Key Findings:
IVC filters reduce the occurrence of pulmonary embolism but do not improve mortality rates, as shown in trials like PREPIC.
Increased risk of deep vein thrombosis associated with IVC filter placement, with rates of DVT reported as high as 21% in some studies.
Potential mortality benefit in specific high-risk subgroups, such as patients with recurrent APE, but not in uncomplicated recurrent DVT.
Complications from IVC filters are common, including access site bleeding (6% to 15%) and long-term DVT (4% to 18%).
Interpretation:
While IVC filters may prevent PE in certain patients, their overall benefit in terms of mortality is limited, and they are associated with significant complications, including high rates of DVT.
Limitations:
Complications can occur frequently and may increase over time, with early complications like access site bleeding in 6% to 15% of patients.
Retrieval rates for IVC filters remain low, with only 15% retrieval at a median of 1.2 years, indicating challenges in follow-up care.
Conclusion:
IVC filters should be used selectively in patients with contraindications to anticoagulation, with a strong emphasis on planned retrieval to minimize complications.
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
